Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ATAI 
ATAI Life Sciences BV (ATAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ATAI (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.29
1 Year Target Price $11.29
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.91% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 992.38M USD | Price to earnings Ratio - | 1Y Target Price 11.29 |
Price to earnings Ratio - | 1Y Target Price 11.29 | ||
Volume (30-day avg) 7 | Beta 1.56 | 52 Weeks Range 1.03 - 5.34 | Updated Date 09/14/2025 |
52 Weeks Range 1.03 - 5.34 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3515.02% |
Management Effectiveness
Return on Assets (TTM) -29.51% | Return on Equity (TTM) -76.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 905659463 | Price to Sales(TTM) 429.79 |
Enterprise Value 905659463 | Price to Sales(TTM) 429.79 | ||
Enterprise Value to Revenue 392.23 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 214338000 | Shares Floating 116368566 |
Shares Outstanding 214338000 | Shares Floating 116368566 | ||
Percent Insiders 7.7 | Percent Institutions 39.81 |
Upturn AI SWOT
ATAI Life Sciences BV
Company Overview
History and Background
ATAI Life Sciences BV was founded in 2018 with the goal of acquiring, incubating, and developing a portfolio of companies focused on psychedelic and non-psychedelic compounds for mental health disorders. It aims to address the significant unmet needs in this area through innovative therapies.
Core Business Areas
- Drug Development: ATAI focuses on developing various therapies, including psychedelic compounds like psilocybin and arketamine, as well as non-psychedelic drugs. They conduct clinical trials to evaluate the safety and efficacy of these treatments.
- Platform Development: ATAI builds a platform to support its portfolio companies, providing resources, expertise, and infrastructure to accelerate drug development.
- Investment and Incubation: ATAI invests in and incubates companies working on innovative approaches to mental health treatment, providing funding and operational support.
Leadership and Structure
The leadership team includes Florian Brand (CEO), Srinivas Rao Katneni (CFO), and key scientific advisors. The organizational structure consists of a central ATAI team that oversees a portfolio of subsidiary and partnered companies.
Top Products and Market Share
Key Offerings
- PCN-101 (R-ketamine): PCN-101, an intravenous R-ketamine, is being investigated for treatment-resistant depression. It is currently in Phase 2 clinical trials. Market share data is currently unavailable as it is still in development. Competitors include Janssen's Spravato (esketamine) and other companies developing ketamine-based therapies.
- RL-007: RL-007 is a Phase 2 ready oral form of N-acetylcystine (NAC), is being investigated for cognitive impairment associated with schizophrenia. Market share data is currently unavailable as it is still in development. Competitors include other companies developing drugs targeting cognitive impairment in schizophrenia, such as Cerevel Therapeutics.
Market Dynamics
Industry Overview
The mental health market is experiencing significant growth, driven by increasing awareness, rising prevalence of mental disorders, and growing demand for innovative treatments. There is a surge in the investment and development of psychedelic-based therapies.
Positioning
ATAI Life Sciences is positioned as a leading player in the emerging psychedelic medicine space, with a diverse portfolio of compounds and a strong focus on clinical development. Its competitive advantage lies in its decentralized business model and diverse approach to tackling mental health challenges
Total Addressable Market (TAM)
The global mental health market is estimated to be worth hundreds of billions of dollars. ATAI is targeting various segments within this market, including depression, anxiety, and substance use disorders. ATAI is well positioned to capitalize on this burgeoning market
Upturn SWOT Analysis
Strengths
- Diversified portfolio of compounds
- Strong scientific team and advisors
- Decentralized business model
- Focus on unmet medical needs
Weaknesses
- Early-stage clinical development risks
- High cash burn rate
- Regulatory uncertainty surrounding psychedelics
- Dependence on successful clinical trial outcomes
Opportunities
- Growing acceptance of psychedelic therapies
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Advancements in drug delivery technologies
Threats
- Competition from established pharmaceutical companies
- Unfavorable regulatory changes
- Clinical trial failures
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- JNJ
- CMPS
- GHRS
- MNMD
Competitive Landscape
ATAI has advantages due to the diversification of its portfolio. The company has disadvantages due to its lack of products in the market to generate revenue. Atai faces competition from companies with approved psychedelic drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the expansion of its portfolio and progression of clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates vary widely depending on the perceived potential of its pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for PCN-101 and RL-007, expanding partnerships with research institutions, and exploring new indications for its compounds.
Summary
ATAI Life Sciences is a high-risk, high-reward company pioneering psychedelic medicine. Their diversified portfolio provides some safety, but success hinges on clinical trials and regulatory approvals. The company is in a high growth space and must continue to expand into new market segments. Investors should monitor cash burn and regulatory developments. It currently has no market share due to no products being in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. Investment in biotech companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ATAI Life Sciences BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-18 | Co-Founder, CEO & Executive Director Dr. Srinivas G. Rao M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://atai.com |
Full time employees 54 | Website https://atai.com | ||
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.